Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex321f2f555.htm |
| EX-31.1 - EX-31.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex31128dafe.htm |
| EX-21.1 - EX-21.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex2116f3db8.htm |
| EX-10.34 - EX-10.34 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex10345030f.htm |
| EX-10.33 - EX-10.33 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex1033b8a5e.htm |
| EX-10.32 - EX-10.32 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex1032e2dfc.htm |
| EX-10.31 - EX-10.31 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex1031f7a64.htm |
| EX-10.30 - EX-10.30 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex103049d78.htm |
| EX-10.15 - EX-10.15 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex1015a1f45.htm |
| EX-4.5 - EX-4.5 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex45b6e3381.htm |
| EX-3.4 - EX-3.4 - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231ex34ff53fc5.htm |
| 10-K - 10-K - NeuroBo Pharmaceuticals, Inc. | nrbo-20191231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
NeuroBo Pharmaceuticals, Inc.
Boston, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-220315 and 333-217296) and Form S-8 (Nos. 333-232667, 333-225435, 333-222675, 333-213946 and 333-213014) of NeuroBo Pharmaceuticals, Inc. (the “Company”) of our report dated March 30, 2020, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Boston, Massachusetts
March 30, 2020